Wanbury Limited

NSE WANBURY.NS

Wanbury Limited Current Liabilities for the year ending March 31, 2024: USD 25.67 M

Wanbury Limited Current Liabilities is USD 25.67 M for the year ending March 31, 2024, a -34.15% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Wanbury Limited Current Liabilities for the year ending March 31, 2023 was USD 38.98 M, a -17.73% change year over year.
  • Wanbury Limited Current Liabilities for the year ending March 31, 2022 was USD 47.38 M, a -2.37% change year over year.
  • Wanbury Limited Current Liabilities for the year ending March 31, 2021 was USD 48.53 M, a 17.58% change year over year.
  • Wanbury Limited Current Liabilities for the year ending March 31, 2020 was USD 41.28 M, a -20.68% change year over year.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
Loading...
SV Wall Street
NSE: WANBURY.NS

Wanbury Limited

CEO Mr. Pradeep Patni
IPO Date Jan. 29, 2007
Location India
Headquarters BSEL Tech Park, B-Wing
Employees 1,491
Sector Healthcare
Industries
Description

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Similar companies

THEMISMED.NS

Themis Medicare Limited

USD 2.62

1.36%

VIMTALABS.NS

Vimta Labs Limited

USD 9.86

2.71%

VENUSREM.NS

Venus Remedies Limited

USD 3.47

1.60%

XPROINDIA.NS

Xpro India Limited

USD 14.57

1.32%

StockViz Staff

February 2, 2025

Any question? Send us an email